Global 
Deutschland Colon to Rectum
J Clin Oncol. 2026;44(5):361-369
Upfront modified FOLFOXIRI plus panitumumab for RAS/BRAF wild-type metastatic colorectal cancer: Final results of the phase III TRIPLETE study
The authors report 5-year results of the phase III randomized TRIPLETE study. Eligible patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC) received first-line modified fluorouracil, leucovorin, oxaliplatin (mFOLFOX)/panitumumab (control group, n = 217) versus modified fluorouracil, leucovorin, oxaliplatin, irinotecan (mFOLFOXIRI)/panitumumab (experimental group, n = 218). The authors present overall survival (OS) and updated outcomes in the intention-to-treat population. The median follow-up was 60.2 months (interquartile range [IQR], 49.3−70.0). The median OS was 41.1 and 33.3 months for experimental and control groups, respectively (hazard ratio [HR] = 0.79; 95% CI: 0.63−0.99; p = 0.049). OS outcomes favored the experimental group regardless of clinical features. No differences in objective response rate (primary end point; 75%/78%, odds ratio = 0.84 [95% CI: 0.54−1.31]; p = 0.442), early tumor shrinkage rate (p = 0.954), depth of response (p = 0.573), no residual tumor resection rate (p = 0.329), and progression-free survival (HR = 0.95 [95% CI: 0.78−1.16]; p = 0.606) were confirmed. Among patients alive at the time of disease progression, the median postprogression survival was 24.6 and 17.7 months for experimental and control groups, respectively (HR = 0.79; 95% CI: 0.62−1.01; p = 0.062). Similar proportions of patients in both groups received subsequent lines of therapy (control/experimental: second line 73%/71%, third line 51%/49%, fourth line 31%/32%), as well as nonpalliative locoregional treatments (control/experimental: 16%/16%). Upfront mFOLFOXIRI/panitumumab significantly improves OS compared with mFOLFOX/panitumumab in patients with RAS/BRAF wild-type mCRC.
DOI: 10.1200/JCO-25-01337